Ji-Nan Guo

Ji-Nan Guo

Auto-generated profile, based on publicly available information

Ji-Nan Guo

Shenzhen People's Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2020 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
JXJing Xie
Jing Xie
JHJian-Sheng Huang
Jian-Sheng Huang
XHXiang-Jiang Huang
Xiang-Jiang Huang
JPJun-Ming Peng
Jun-Ming Peng
ZYZhou Yu
Zhou Yu
JGJi-Nan Guo
Ji-Nan Guo
Background: The dogma that urine is sterile in healthy individuals has been overturned by recent studies applying molecular-based methods. Mounting evidences indicate that dysbiosis of the urinary microbiota is associated with several urological diseases. In this study, we aimed to investigate the urinary microbiome of male patients with calcium-based kidney stones and compare it with those of healthy individuals. Results: The diversity of the urinary microbiota in kidney stone patients was significantly lower than that of healthy controls based on the Shannon and Simpson index (P < 0.001 for both indices). The urinary microbiota structure also significantly differed between kidney stone patients and healthy controls (ANOSIM, R = 0.11, P < 0.001). Differential representation of inflammation associated bacteria (e.g., Acinetobacter) and several enriched functional pathways were identified in the urine of kidney stones patients. Meanwhile, we found the species diversity, overall composition of microbiota and predicted functional pathways were similar between bladder urine and renal pelvis urine in kidney stone patients. Conclusions: A marked dysbiosis of urinary microbiota in male patients with calcium-based kidney stones was observed, which may be helpful to interpret the association between bacteria and calcium-based kidney stones.

1 December 2018 in International Journal of Surgery
Verified
Journal Article
Closed access
JGJinan Guo
Jinan Guo
JFJiequn Fang
Jiequn Fang
XHXiangjiang Huang
Xiangjiang Huang
YLYanfeng Liu
Yanfeng Liu
YYYeqing Yuan
Yeqing Yuan
JWJianhong Wang
Jianhong Wang
The prognostic role of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients with prostate cancer (PCa) remains inconsistent. Here we quantify the prognostic impact of these biomarkers and assess their consistency in PCa. We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated. A total of 7228 patients from 18 studies were included in the meta-analysis. Overall, elevated pretreatment NLR was associated with poor overall survival (OS, HR 1.58, 95% CI 1.41-1.78, P < 0.001), progression-free survival (PFS, HR 1.95, 95% CI 1.53-2.49, P < 0.001) and biochemical recurrence-free survival (BRFS, HR 1.37, 95% CI 1.07-1.75, P = 0.011). And high pretreatment PLR was correlated with more inferior PFS (HR 1.62, 95% CI 1.20-2.19, P = 0.002), OS (HR 1.70, 95% CI 1.34-2.15, P < 0.001) and cancer-specific survival (CSS, HR 2.02, 95% CI 1.24-3.29, P = 0.005). Moreover, the subgroup analyses did not alter the direction of results for OS and PFS. Based on these findings, elevated NLR and PLR was associated with poor oncologic outcomes, and they can serve as prognostic factors in PCa patients.

1 June 2018 in EBioMedicine
Verified
Journal Article
Open access
WXWenjing Xiao
Wenjing Xiao
NDNan Du
Nan Du
THTaoyuan Huang
Taoyuan Huang
JGJinan Guo
Jinan Guo
XMXingkui Mo
Xingkui Mo
JCJing Chen
Jing Chen
TP53 has been proved to be associated with cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastatic melanoma by analyzing the data from one public cohort consisting of 110 patients with metastatic melanoma. The sequencing, mRNA and survival data of 368 patients with skin melanoma from The Cancer Genome Atlas (TCGA) was used to explore the underlying mechanism. TP53 mutation was associated with significant poorer progression-free survival (HR, 2.25; 95% CI, 1.15-4.37; P = 0.014), poorer overall survival (HR, 2.05; 95% CI, 1.02-4.13; P = 0.040) and trend of poorer response (OR, 0.20; 95% CI, 0.02-1.62; P = 0.131). The correlations were significant in multivariate analysis including lactate dehydrogenase, tumor mutational burden and tumor stage (P < 0.05). In TCGA, no association was observed between TP53 mutation and survival (P = 0.55). The mRNA expression of FAS was lower in patients with TP53 mutation than TP53 wild-type. Our findings suggest that TP53 mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade.

8 April 2019 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
KLKaisheng Liu
Kaisheng Liu
ZZZhifan Zhou
Zhifan Zhou
HGHengyuan Gao
Hengyuan Gao
FYFang Yang
Fang Yang
YQYajun Qian
Yajun Qian
RCRui Chen
Rui Chen

11 April 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
XYXinqing Ye
Xinqing Ye
JGJinan Guo
Jinan Guo
HZHongxiang Zhang
Hongxiang Zhang
QMQinggui Meng
Qinggui Meng
YMYun Ma
Yun Ma
JCJiwen Cheng
Jiwen Cheng

1 March 2018 in Anticancer Research
Verified
Journal Article
Open access
PDF file
JGJinan Guo
Jinan Guo
JYJianggen Yang
Jianggen Yang
XZXuhui Zhang
Xuhui Zhang
XFXiaoyan Feng
Xiaoyan Feng
HZHeqiu Zhang
Heqiu Zhang
KXKefeng Xiao
Kefeng Xiao
Background/Aim: Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. Materials and Methods: We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. Results: The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). Conclusion: The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings.